Subject terms
mCRC, cancer
CANCER, METASTATIC COLORECTAL CANCER
Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil (FTD/TPI), we identified A combination of real-world evidence and a reanalysis of phase 3 clinical trial data unveils 